PubMed:1490197 JSONTXT

{"project":"LitCoin-PubTator-for-Tuning","denotations":[{"id":"3","span":{"begin":38,"end":49},"obj":"ChemicalEntity"},{"id":"4","span":{"begin":54,"end":66},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5","span":{"begin":70,"end":76},"obj":"OrganismTaxon"},{"id":"18","span":{"begin":157,"end":168},"obj":"ChemicalEntity"},{"id":"19","span":{"begin":183,"end":195},"obj":"DiseaseOrPhenotypicFeature"},{"id":"20","span":{"begin":213,"end":219},"obj":"OrganismTaxon"},{"id":"21","span":{"begin":427,"end":438},"obj":"ChemicalEntity"},{"id":"22","span":{"begin":483,"end":494},"obj":"ChemicalEntity"},{"id":"23","span":{"begin":528,"end":540},"obj":"DiseaseOrPhenotypicFeature"},{"id":"24","span":{"begin":612,"end":623},"obj":"ChemicalEntity"},{"id":"25","span":{"begin":1070,"end":1081},"obj":"ChemicalEntity"},{"id":"26","span":{"begin":1187,"end":1191},"obj":"OrganismTaxon"},{"id":"27","span":{"begin":1207,"end":1216},"obj":"DiseaseOrPhenotypicFeature"},{"id":"28","span":{"begin":1354,"end":1366},"obj":"DiseaseOrPhenotypicFeature"},{"id":"29","span":{"begin":1405,"end":1416},"obj":"ChemicalEntity"}],"attributes":[{"id":"A24","pred":"tao:has_database_id","subj":"24","obj":"MESH:C048341"},{"id":"A23","pred":"tao:has_database_id","subj":"23","obj":"MESH:D005334"},{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"MESH:C048341"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"MESH:D005334"},{"id":"A5","pred":"tao:has_database_id","subj":"5","obj":"Tax:10090"},{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"MESH:C048341"},{"id":"A22","pred":"tao:has_database_id","subj":"22","obj":"MESH:C048341"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"Tax:10090"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"MESH:C048341"},{"id":"A28","pred":"tao:has_database_id","subj":"28","obj":"MESH:D005334"},{"id":"A4","pred":"tao:has_database_id","subj":"4","obj":"MESH:D005334"},{"id":"A3","pred":"tao:has_database_id","subj":"3","obj":"MESH:C048341"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"MESH:D007938"},{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"Tax:10090"},{"id":"A18","pred":"tao:has_database_id","subj":"18","obj":"MESH:C048341"}],"text":"The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.\nThe in vitro purging effect of mafosfamide combined with hyperthermia was studied in a murine model. The survival of normal clonogenic progenitors (d-9 CFU-S and CFU-GM) and WEHI 3-B leukaemic clonogenic cells (CFU-L) were compared. At 37 degrees C, CFU-L proved to be significantly more sensitive to mafosfamide than either of the normal progenitors. When mafosfamide was combined with 42.5 degrees C hyperthermia for 1 h, an additive effect was observed: at a dose of 5 micrograms/ml mafosfamide, the survival of CFU-L was nearly two logs lower than that observed at 37 degrees C, while 37.7% of CFU-S survived the purging. The repopulating capacity of surviving bone marrow CFU-S was not altered: a similar 60 d survival of supralethally irradiated recipients transplanted with comparable graft sizes from purged or non-purged bone marrow was observed. When bone marrow suspensions containing WEHI 3-B cells were purged with 5 micrograms/ml mafosfamide at 42.5 degrees C and the minimal amount of bone marrow cells needed to protect supralethally irradiated mice were injected, leukaemia incidence was reduced to less than 10% as opposed to 100% of those injected with untreated bone marrow. Our results suggest that ex vivo hyperthermia may enhance the purging efficiency of mafosfamide."}

{"project":"LitCoin-Disease-Tuning-1","denotations":[{"id":"T1","span":{"begin":54,"end":66},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":183,"end":195},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":528,"end":540},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":1207,"end":1216},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":1354,"end":1366},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A2","pred":"ID:","subj":"T2","obj":"D000084462"},{"id":"A3","pred":"ID:","subj":"T3","obj":"D000084462"},{"id":"A5","pred":"ID:","subj":"T5","obj":"D000084462"},{"id":"A4","pred":"ID:","subj":"T4","obj":"DISEASE"},{"id":"A1","pred":"ID:","subj":"T1","obj":"D000084462"}],"text":"The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.\nThe in vitro purging effect of mafosfamide combined with hyperthermia was studied in a murine model. The survival of normal clonogenic progenitors (d-9 CFU-S and CFU-GM) and WEHI 3-B leukaemic clonogenic cells (CFU-L) were compared. At 37 degrees C, CFU-L proved to be significantly more sensitive to mafosfamide than either of the normal progenitors. When mafosfamide was combined with 42.5 degrees C hyperthermia for 1 h, an additive effect was observed: at a dose of 5 micrograms/ml mafosfamide, the survival of CFU-L was nearly two logs lower than that observed at 37 degrees C, while 37.7% of CFU-S survived the purging. The repopulating capacity of surviving bone marrow CFU-S was not altered: a similar 60 d survival of supralethally irradiated recipients transplanted with comparable graft sizes from purged or non-purged bone marrow was observed. When bone marrow suspensions containing WEHI 3-B cells were purged with 5 micrograms/ml mafosfamide at 42.5 degrees C and the minimal amount of bone marrow cells needed to protect supralethally irradiated mice were injected, leukaemia incidence was reduced to less than 10% as opposed to 100% of those injected with untreated bone marrow. Our results suggest that ex vivo hyperthermia may enhance the purging efficiency of mafosfamide."}

{"project":"LitCoin-PubTator_CellLine","denotations":[{"id":"T1","span":{"begin":300,"end":306},"obj":"CellLine"},{"id":"T2","span":{"begin":1022,"end":1028},"obj":"CellLine"}],"attributes":[{"id":"A1","pred":"cellosaurus_accession_id","subj":"T1","obj":"CVCL_3622"},{"id":"A2","pred":"cellosaurus_accession_id","subj":"T2","obj":"CVCL_3622"}],"text":"The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.\nThe in vitro purging effect of mafosfamide combined with hyperthermia was studied in a murine model. The survival of normal clonogenic progenitors (d-9 CFU-S and CFU-GM) and WEHI 3-B leukaemic clonogenic cells (CFU-L) were compared. At 37 degrees C, CFU-L proved to be significantly more sensitive to mafosfamide than either of the normal progenitors. When mafosfamide was combined with 42.5 degrees C hyperthermia for 1 h, an additive effect was observed: at a dose of 5 micrograms/ml mafosfamide, the survival of CFU-L was nearly two logs lower than that observed at 37 degrees C, while 37.7% of CFU-S survived the purging. The repopulating capacity of surviving bone marrow CFU-S was not altered: a similar 60 d survival of supralethally irradiated recipients transplanted with comparable graft sizes from purged or non-purged bone marrow was observed. When bone marrow suspensions containing WEHI 3-B cells were purged with 5 micrograms/ml mafosfamide at 42.5 degrees C and the minimal amount of bone marrow cells needed to protect supralethally irradiated mice were injected, leukaemia incidence was reduced to less than 10% as opposed to 100% of those injected with untreated bone marrow. Our results suggest that ex vivo hyperthermia may enhance the purging efficiency of mafosfamide."}

{"project":"LitEisuke","denotations":[{"id":"T1","span":{"begin":54,"end":66},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":183,"end":195},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":528,"end":540},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":1207,"end":1216},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":1354,"end":1366},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A3","pred":"#label","subj":"T3","obj":"D000084462"},{"id":"A1","pred":"#label","subj":"T1","obj":"D000084462"},{"id":"A4","pred":"#label","subj":"T4","obj":"DISEASE"},{"id":"A2","pred":"#label","subj":"T2","obj":"D000084462"},{"id":"A5","pred":"#label","subj":"T5","obj":"D000084462"}],"text":"The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.\nThe in vitro purging effect of mafosfamide combined with hyperthermia was studied in a murine model. The survival of normal clonogenic progenitors (d-9 CFU-S and CFU-GM) and WEHI 3-B leukaemic clonogenic cells (CFU-L) were compared. At 37 degrees C, CFU-L proved to be significantly more sensitive to mafosfamide than either of the normal progenitors. When mafosfamide was combined with 42.5 degrees C hyperthermia for 1 h, an additive effect was observed: at a dose of 5 micrograms/ml mafosfamide, the survival of CFU-L was nearly two logs lower than that observed at 37 degrees C, while 37.7% of CFU-S survived the purging. The repopulating capacity of surviving bone marrow CFU-S was not altered: a similar 60 d survival of supralethally irradiated recipients transplanted with comparable graft sizes from purged or non-purged bone marrow was observed. When bone marrow suspensions containing WEHI 3-B cells were purged with 5 micrograms/ml mafosfamide at 42.5 degrees C and the minimal amount of bone marrow cells needed to protect supralethally irradiated mice were injected, leukaemia incidence was reduced to less than 10% as opposed to 100% of those injected with untreated bone marrow. Our results suggest that ex vivo hyperthermia may enhance the purging efficiency of mafosfamide."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":183,"end":195},"obj":"HP_0001945"},{"id":"T2","span":{"begin":528,"end":540},"obj":"HP_0001945"},{"id":"T3","span":{"begin":1354,"end":1366},"obj":"HP_0001945"}],"text":"The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.\nThe in vitro purging effect of mafosfamide combined with hyperthermia was studied in a murine model. The survival of normal clonogenic progenitors (d-9 CFU-S and CFU-GM) and WEHI 3-B leukaemic clonogenic cells (CFU-L) were compared. At 37 degrees C, CFU-L proved to be significantly more sensitive to mafosfamide than either of the normal progenitors. When mafosfamide was combined with 42.5 degrees C hyperthermia for 1 h, an additive effect was observed: at a dose of 5 micrograms/ml mafosfamide, the survival of CFU-L was nearly two logs lower than that observed at 37 degrees C, while 37.7% of CFU-S survived the purging. The repopulating capacity of surviving bone marrow CFU-S was not altered: a similar 60 d survival of supralethally irradiated recipients transplanted with comparable graft sizes from purged or non-purged bone marrow was observed. When bone marrow suspensions containing WEHI 3-B cells were purged with 5 micrograms/ml mafosfamide at 42.5 degrees C and the minimal amount of bone marrow cells needed to protect supralethally irradiated mice were injected, leukaemia incidence was reduced to less than 10% as opposed to 100% of those injected with untreated bone marrow. Our results suggest that ex vivo hyperthermia may enhance the purging efficiency of mafosfamide."}